|
|
|
|
|
|
|
|
|
|
"The revised recommendations apply to epoetin alfa, which is marketed as Epogen and Procrit, and to darbepoetin alfa, marketed as Aranesp."
Saturday, June 25, 2011
Safety Concerns Prompt New Recommendations for Anemia Drugs « news@JAMA (patients with chronic kidney disease)
"The revised recommendations apply to epoetin alfa, which is marketed as Epogen and Procrit, and to darbepoetin alfa, marketed as Aranesp."
Subscribe to:
Post Comments
(
Atom
)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.